Mr. Marc Lemieux reports

GROUPE TECHNOLOGIQUE KDA ANNOUNCES A STRATEGIC COLLABORATION WITH PHARMACIE HORIZON SANTE AND DR. ERIC POIRIER TO OPTIMIZE ONCOLOGY TREATMENT MANAGEMENT

KDA Group Inc.'s subsidiary, Groupe Technologique KDA (Tech KDA), in partnership with Pharmacie Horizon Sante and Dr. Eric Poirier, surgical oncologist practicing at the Clinique des Maladies du Sein at the Centre Hospitalier Universitaire de Quebec (CHU de Quebec-Universite Laval), has signed a letter of intent, dated Dec. 11, 2024, to integrate the innovative Medherize platform. This project aims to address the complex challenges associated with managing outpatient oncology treatments for breast cancer patients.

Pharmacie Horizon Sante, a pharmaceutical distributor specializing in specialty medications and a network of independent pharmacists with 23 affiliated pharmacies across Quebec, brings valuable expertise in community pharmacy. This collaboration combines the complementary strengths of Pharmacie Horizon Sante, Dr. Eric Poirier's oncology expertise and Tech KDA's technological development capabilities. Together, they aim to optimize the management of complex oncology treatments by integrating proximity pharmaceutical care, specialized medical expertise and innovative technological solutions.

Pharmacie Horizon Sante introduces a unique hybrid approach to managing and monitoring specialty medications. This innovative method combines the best of both worlds: patients retain access to their usual community pharmacies for collecting their regular and specialty medications while benefiting from structured follow-up provided by specialized support pharmacies.

Managing patients undergoing oncology treatments is inherently complex, requiring rigorous monitoring (blood tests, liver assessments, electrocardiograms (ECGs)) and efficient coordination despite health care professionals' heavy workloads and the risks of treatment discontinuation due to side effects or frequent adjustments.

To address these challenges, Tech KDA developed Medherize, an integrated solution within its Adherize+ platform. Medherize simplifies coordination between patients and health care professionals through real-time tracking, Dossier Sante Quebec (DSQ) and ECG data integration, and rapid, precise adjustments.

Based on validated protocols, Medherize offers automated interventions to manage side effects such as neutropenia or diarrhea, providing all stakeholders with shared access to a common timeline to maximize care efficiency.

Finally, Medherize will soon extend its capabilities to manage specialty medications for complex treatments, including:

• Biotherapies;
• Oncology therapies;
• Medications for autoimmune diseases;
• Medications for rare genetic diseases.

Yves Marmet, president of Tech KDA, stated, "With Medherize, we address critical oncology challenges while providing health care professionals with powerful tools to simplify the management of complex care."

Jerome-Henri Lavoie, general manager of Pharmacie Horizon Sante, added, "This collaboration embodies our vision: to provide practical and innovative solutions to the challenges of specialized treatments while focusing on patients and their freedom to choose their health care professionals."

Dr. Eric Poirier, surgical oncologist at CHU de Quebec-Universite Laval, commented, "Medherize introduces an integrated and innovative approach that meets patient needs while supporting health care professionals in their daily practice."

About KDA Group Inc.

KDA Group is a leader in technological innovations and specialized software solutions (SaaS -- software-as-a-service) for the health care professionals' market. KDA is a corporation that offers quality products and has respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the health care's digital transformation, and are available for the Canadian and international markets.

We seek Safe Harbor.